The Efficacy of Anti-TNFs in Immune-Mediated Disease

Abstract

TNF-α is produced in high concentrations in chronic inflammatory disease, resulting in excessive inflammation which eventually leads to organ damage. The advent of anti-TNF therapy in clinical practice 20 years ago represented a significant change in the management of immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis (RA), axial spondylarthritis (SpA), psoriasis, and inflammatory bowel disease (IBD). There are five anti-TNFs approved for use in IMIDs: infliximab, adalimumab, golimumab, etanercept, and certolizumab pegol. The structural and pharmacological differences between these agents mean that they can have differential efficacy across IMIDs, and therefore the indications for which they are approved vary. This mini-review aims to summarise the current understanding of anti-TNF efficacy in those IMIDs for which they are approved, focussing on data from meta-analyses of randomised clinical trials (RCTs), and real-world studies.

Patient Experience with the SensoReady® Autoinjector Pen versus a Comparator Device: Results from a Canadian Patient Survey in Rheumatoid Arthritis and Crohn´s Disease

“…TNF-α biologics, such as adalimumab, have been a key part of the treatment algorithms for RA and CD for several decades. 1,3 Most biologic therapies for IMIDs, including adalimumab, are delivered subcutaneously via devices such as prefilled syringes or autoinjectors, both of which allow for convenient self-administration by patients. 4,5 Previous studies have reported patient preference for autoinjectors over prefilled syringes, in terms of reduced discomfort, ease of use, and improved adherence.…”

“…TNF-α biologics, such as adalimumab, have been a key part of the treatment algorithms for RA and CD for several decades. 1 , 3 …”